Indian Supreme Court stops Glenmark from making generic Januvia

The Supreme Court of India has ordered Glenmark Pharmaceuticals to stop making generic versions of Merck Sharp & Dohme’s diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

Novo Nordisk secures China win ahead of key patent expiration

6 January 2026 Danish pharma giant notches an important victory in a huge market for semaglutide, but faces a patent cliff and mounting challenges across India, Canada and the US.

Asia

Novo Nordisk ramps up semaglutide defence as generics lurk

9 December 2025 The Danish pharma giant is expanding its patent defence in India as multiple generics prepare to challenge its blockbuster diabetes and weight-loss drug ahead of 2026 patent expiry.

Asia

Novo Nordisk India strategy suffers semaglutide patent setback

4 December 2025 The Delhi High Court has denied an injunction against an Indian generic manufacturer, finding credible challenges to the validity of Novo's semaglutide patent—flagging concerns over obviousness, double patenting, and evergreening.

More features

Senior four-partner team leaves A&O Shearman

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Senior USPTO solicitor steps into private practice

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Indian Supreme Court stops Glenmark from making generic Januvia

More on this story

Editor's picks

Editor's picks

More features